Taysha Gene Therapies (TSHA) Debt to Equity: 2022-2025
Historic Debt to Equity for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $0.23.
- Taysha Gene Therapies' Debt to Equity fell 52.01% to $0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.23, marking a year-over-year decrease of 52.01%. This contributed to the annual value of $0.61 for FY2024, which is 13.65% up from last year.
- Latest data reveals that Taysha Gene Therapies reported Debt to Equity of $0.23 as of Q3 2025, which was up 40.70% from $0.17 recorded in Q2 2025.
- In the past 5 years, Taysha Gene Therapies' Debt to Equity registered a high of $40.01 during Q4 2022, and its lowest value of -$3.65 during Q3 2023.
- For the 3-year period, Taysha Gene Therapies' Debt to Equity averaged around -$0.30, with its median value being $0.35 (2024).
- Its Debt to Equity has fluctuated over the past 5 years, first tumbled by 446.49% in 2023, then skyrocketed by 133.63% in 2024.
- Quarterly analysis of 4 years shows Taysha Gene Therapies' Debt to Equity stood at $40.01 in 2022, then tumbled by 98.65% to $0.54 in 2023, then climbed by 13.65% to $0.61 in 2024, then crashed by 52.01% to $0.23 in 2025.
- Its Debt to Equity stands at $0.23 for Q3 2025, versus $0.17 for Q2 2025 and $0.77 for Q1 2025.